Dynavax Technologies (DVAX) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
277.2M
Gross Profit
227.8M
82.17%
Operating Income
-4.1M
-1.49%
Net Income
27.3M
9.85%
Balance Sheet Metrics
Total Assets
986.3M
Total Liabilities
389.5M
Shareholders Equity
596.8M
Debt to Equity
0.65
Cash Flow Metrics
Operating Cash Flow
70.0M
Free Cash Flow
60.2M
Revenue & Profitability Trend
Dynavax Technologies Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 277.2M | 232.3M | 722.7M | 439.4M | 46.6M |
| Cost of Goods Sold | 49.4M | 50.2M | 262.2M | 173.6M | 13.9M |
| Gross Profit | 227.8M | 182.1M | 460.5M | 265.9M | 32.6M |
| Operating Expenses | 231.9M | 207.8M | 178.0M | 132.4M | 107.9M |
| Operating Income | -4.1M | -25.7M | 282.5M | 133.5M | -75.2M |
| Pre-tax Income | 30.9M | -4.4M | 294.3M | 77.5M | -75.2M |
| Income Tax | 3.5M | 2.0M | 1.1M | 808.0K | 0 |
| Net Income | 27.3M | -6.4M | 293.2M | 76.7M | -75.2M |
| EPS (Diluted) | - | -$0.05 | $1.97 | $0.57 | -$0.78 |
Income Statement Trend
Dynavax Technologies Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 848.9M | 859.1M | 917.0M | 972.5M | 290.0M |
| Non-Current Assets | 137.3M | 138.0M | 68.9M | 66.7M | 63.3M |
| Total Assets | 986.3M | 997.1M | 985.8M | 1.0B | 353.3M |
| Liabilities | |||||
| Current Liabilities | 78.6M | 62.2M | 150.1M | 556.4M | 77.4M |
| Non-Current Liabilities | 310.8M | 312.8M | 254.8M | 260.5M | 217.2M |
| Total Liabilities | 389.5M | 375.0M | 404.8M | 816.9M | 294.6M |
| Equity | |||||
| Total Shareholders Equity | 596.8M | 622.1M | 581.0M | 222.4M | 58.7M |
Balance Sheet Composition
Dynavax Technologies Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 27.3M | -6.4M | 293.2M | 76.7M | -75.2M |
| Operating Cash Flow | 70.0M | 90.7M | -66.5M | 305.1M | -53.2M |
| Investing Activities | |||||
| Capital Expenditures | -6.4M | -4.1M | -7.1M | -9.5M | -4.1M |
| Investing Cash Flow | -18.0M | -154.9M | -317.0M | 13.2M | -26.4M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | -109.3M | -6.5M | 0 | 30.5M | 108.5M |
| Free Cash Flow | 60.2M | 96.5M | 55.6M | 326.1M | -103.3M |
Cash Flow Trend
Dynavax Technologies Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
54.60
Forward P/E
29.39
Price to Book
2.47
Price to Sales
4.31
PEG Ratio
29.39
Profitability Ratios
Profit Margin
-20.39%
Operating Margin
-31.40%
Return on Equity
-10.45%
Return on Assets
-0.07%
Financial Health
Current Ratio
11.93
Debt to Equity
54.64
Beta
1.04
Per Share Data
EPS (TTM)
-$0.50
Book Value per Share
$4.29
Revenue per Share
$2.29
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| dvax | 1.3B | 54.60 | 2.47 | -10.45% | -20.39% | 54.64 |
| Zoetis | 70.3B | 28.34 | 15.12 | 52.09% | 27.12% | 145.63 |
| Haleon Plc - ADR | 45.5B | 23.37 | 5.63 | 8.95% | 12.84% | 63.41 |
| Supernus | 1.8B | 28.53 | 1.72 | 6.32% | 9.27% | 3.13 |
| Indivior PLC | 1.9B | 530.50 | -6.57 | -0.57% | -5.30% | -1.29 |
| Bausch Health | 2.6B | -50.69 | -9.95 | 14.29% | -0.41% | -89.63 |
Financial data is updated regularly. All figures are in the company's reporting currency.